SCHEMBL20609293

SCHEMBL20609293

CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H](n2c3ccccc3c3c4c(c5c6ccccc6[nH]c5c32)CNC4=O)O[C@@H]1C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 13/20 0.65
ROCK2 O75116 8/20 0.64
PRKCA P17252 12/20 0.59
PRKD3 O94806 8/20 0.59
EGFR P00533 8/20 0.59
PRKCG P05129 8/20 0.59
PRKCB P05771 8/20 0.59
PRKACA P17612 8/20 0.59
PRKACB P22694 8/20 0.59
PRKCH P24723 8/20 0.59
PRKCI P41743 8/20 0.59
PRKCE Q02156 8/20 0.59
PRKCZ Q05513 8/20 0.59
PRKCD Q05655 8/20 0.59
PRKD1 Q15139 8/20 0.59
PRKACG P22612 7/20 0.59
NTRK1 P04629 3/20 0.59
KDR P35968 3/20 0.59
SRC P12931 2/20 0.59
PLK4 O00444 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20048217 0.84 PRKCQ (0.69) PRKCQROCK2PRKCAPRKD3EGFR
SCHEMBL22970010 0.84 PRKCQ (0.69) PRKCQROCK2PRKCAPRKD3EGFR
SCHEMBL16946994 0.84 PRKCQ (0.69) PRKCQROCK2PRKCAPRKD3EGFR
SCHEMBL24105686 0.84 PRKCQ (0.69) PRKCQROCK2PRKCAPRKD3EGFR
SCHEMBL20412063 0.84 PRKCQ (0.69) PRKCQROCK2PRKCAPRKD3EGFR
SCHEMBL14231500 0.83 ROCK2 (0.70) PRKCQROCK2PRKCAPRKD3EGFR
SCHEMBL12570606 0.81 PRKCQ (0.85) PRKCQROCK2PRKCANTRK1KDR
SCHEMBL12570608 0.81 PRKCQ (0.85) PRKCQROCK2PRKCANTRK1KDR
SCHEMBL12570349 0.81 PRKCQ (0.85) PRKCQROCK2PRKCANTRK1KDR
SCHEMBL30885079 0.79 PRKCQ (1.00) PRKCQROCK2PRKCANTRK1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10166241-B2 Combination Therapy III TURUN YLIOPISTO (FI) 2019-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10166241-B2 Combination Therapy III HDAC4, HDAC3, HDAC5 PRKCQ 2351/4885ROCK2 1801/4885PRKCA 1625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.